Cox regression analysis of the training cohort
| Univariable Cox . | OS . | NRM . | TTR . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| EASIX-1y (twofold increase) | 1.50 | 1.26-1.74 | <.001 | 1.74 | 1.45-2.08 | < .001 | 0.95 | 0.76-1.17 | .618 |
| Multivariable Cox | n = 550, events = 125 | n = 550, events = 91 | n = 550, events = 66 | ||||||
| EASIX-1y (twofold increase) | 1.45 | 1.22-1.72 | < .001 | 1.68 | 1.34-2.10 | < .001 | 0.94 | 0.75-1.19 | .610 |
| Age above 50 y (yes vs no) | 1.68 | 1.12-2.51 | .011 | 2.02 | 1.16-3.54 | .014 | 1.30 | 0.82-2.07 | .266 |
| Recipient sex (male vs female) | 0.98 | 0.68-1.42 | .908 | 0.99 | 0.59-1.65 | .959 | 1.11 | 0.72-1.73 | .630 |
| HLA-mismatch (yes vs no) | 1.19 | 0.75-1.90 | .455 | 1.61 | 0.87-2.99 | .131 | 1.14 | 0.66-1.99 | .634 |
| RIC (yes vs no) | 1.20 | 0.68-2.12 | .520 | 1.31 | 0.60-2.88 | .495 | 0.80 | 0.43-1.49 | .479 |
| ATG (yes vs no) | 0.73 | 0.49-1.09 | .127 | 0.65 | 0.38-1.16 | .144 | 0.66 | 0.42-1.04 | .072 |
| MTX (yes vs no) | 0.80 | 0.53-1.19 | .269 | 0.62 | 0.35-1.09 | .096 | 0.86 | 0.53-1.38 | .533 |
| Diagnosis (myeloid vs lymphoid) | 0.96 | 0.66-1.39 | .819 | 1.24 | 0.75-2.07 | .403 | 0.57 | 0.36-0.89 | .013 |
| History of acute GVHD | 1.77 | 1.23-2.53 | .002 | 1.65 | 1.00-2.71 | .051 | 1.42 | 0.93-2.16 | .103 |
| Univariable Cox . | OS . | NRM . | TTR . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| EASIX-1y (twofold increase) | 1.50 | 1.26-1.74 | <.001 | 1.74 | 1.45-2.08 | < .001 | 0.95 | 0.76-1.17 | .618 |
| Multivariable Cox | n = 550, events = 125 | n = 550, events = 91 | n = 550, events = 66 | ||||||
| EASIX-1y (twofold increase) | 1.45 | 1.22-1.72 | < .001 | 1.68 | 1.34-2.10 | < .001 | 0.94 | 0.75-1.19 | .610 |
| Age above 50 y (yes vs no) | 1.68 | 1.12-2.51 | .011 | 2.02 | 1.16-3.54 | .014 | 1.30 | 0.82-2.07 | .266 |
| Recipient sex (male vs female) | 0.98 | 0.68-1.42 | .908 | 0.99 | 0.59-1.65 | .959 | 1.11 | 0.72-1.73 | .630 |
| HLA-mismatch (yes vs no) | 1.19 | 0.75-1.90 | .455 | 1.61 | 0.87-2.99 | .131 | 1.14 | 0.66-1.99 | .634 |
| RIC (yes vs no) | 1.20 | 0.68-2.12 | .520 | 1.31 | 0.60-2.88 | .495 | 0.80 | 0.43-1.49 | .479 |
| ATG (yes vs no) | 0.73 | 0.49-1.09 | .127 | 0.65 | 0.38-1.16 | .144 | 0.66 | 0.42-1.04 | .072 |
| MTX (yes vs no) | 0.80 | 0.53-1.19 | .269 | 0.62 | 0.35-1.09 | .096 | 0.86 | 0.53-1.38 | .533 |
| Diagnosis (myeloid vs lymphoid) | 0.96 | 0.66-1.39 | .819 | 1.24 | 0.75-2.07 | .403 | 0.57 | 0.36-0.89 | .013 |
| History of acute GVHD | 1.77 | 1.23-2.53 | .002 | 1.65 | 1.00-2.71 | .051 | 1.42 | 0.93-2.16 | .103 |
ATG, antithymocyte globulin; MTX, methotrexate; RIC, reduced-intensity conditioning; 95% CI, 95% confidence interval.